First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives
2024

First-line treatments for KRAS-mutant non-small cell lung cancer

publication Evidence: moderate

Author Information

Author(s): He Qi, Liu Xiaoyan, Jiang Liyan, Liu Ping, Xuan Weixia, Wang Yudong, Meng Rui, Feng Huijing, Lv Shuang, Miao Qian, Zheng Di, Xu Yan, Wang Mengzhao

Primary Institution: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Hypothesis

What are the current and future perspectives for treating KRAS-mutant non-small cell lung cancer?

Conclusion

First-line immunotherapy is more effective than chemotherapy for KRAS-mutant non-small cell lung cancer.

Supporting Evidence

  • KRAS mutations are common in non-small cell lung cancer and affect treatment outcomes.
  • Immunotherapy may provide better survival rates for patients with KRAS mutations compared to traditional chemotherapy.
  • Combining chemotherapy with immunotherapy shows promise for improving treatment efficacy.

Takeaway

Doctors are finding better ways to treat a type of lung cancer that has a specific gene change, using new medicines that help the body's immune system fight the cancer.

Methodology

This review summarizes current evidence on first-line therapies for KRAS-mutant non-small cell lung cancer and compares treatment outcomes and biomarkers.

Limitations

The review highlights inconsistencies in previous studies due to the heterogeneity of KRAS-mutant non-small cell lung cancer.

Digital Object Identifier (DOI)

10.1080/15384047.2024.2441499

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication